Evidence map›Paper›PMID 33592120›Full record

ReviewCA: a cancer journal for clinicians2021

Current treatment and recent progress in gastric cancer.

Smita S Joshi, Brian D Badgwell

2 registry-linked trialsOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CA: a cancer journal for clinicians, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,173 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,173citing papers in PubMed, 6 pooled it
203.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05161572 phase2terminatednot on this map

A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma

TypeinterventionalSponsorFudan UniversityRan2021 to 2022Enrolled6ConditionsStomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, ChemoradiotherapyArmsOxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab, Concurrent chemoradiation, D2/R0 gastrectomy
NCT06490055 completednot on this map

Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer.

Typeobservational_patient_registrySponsorCity of Hope Medical CenterRan2018 to 2025Enrolled162ConditionsGastric Cancer, Chemotherapy Effect, Paclitaxel, RamucirumabArmsPaclitaxel
3 · Its place in the literature

Who cites it

1,173 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,701 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Cell adhesion & migration · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1,113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Smita S JoshiGastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Brian D BadgwellDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9915-8355
Memorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Holly Clegg Gastric Cancer Research FundNCI NIH HHS P30 CA008748No Stomach for Cancer Research Fund Philanthropy
6 · The paper itself

Abstract

Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard-of-care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.

Indexed as

Esophagogastric JunctionAdenocarcinomaAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemoradiotherapy, AdjuvantChemotherapy, AdjuvantDNA Mismatch RepairErb-b2 Receptor Tyrosine KinasesGastrectomyHumansImmune Checkpoint InhibitorsMicrosatellite InstabilityMutationNeoadjuvant TherapyAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint Inhibitorsadenocarcinomagastric cancerimmunotherapymolecular subtypesstomach neoplasms

Identifiers

PMID33592120
PMCPMC9927927
OpenAlexW3129551551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.